BioCardia (NASDAQ:BCDA) Director Simon Stertzer Buys 70,200 Shares of Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer purchased 70,200 shares of the stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $0.92 per share, for a total transaction of $64,584.00. Following the transaction, the director directly owned 127,338 shares of the company’s stock, valued at $117,150.96. This represents a 122.86% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

BioCardia Stock Up 6.0%

Shares of BioCardia stock traded up $0.06 on Wednesday, reaching $1.06. The company’s stock had a trading volume of 489,451 shares, compared to its average volume of 1,516,771. The company has a market capitalization of $12.06 million, a P/E ratio of -1.16 and a beta of 0.51. The stock has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.18. BioCardia, Inc. has a 52-week low of $0.78 and a 52-week high of $2.45.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Sell-side analysts forecast that BioCardia, Inc. will post -0.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCardia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. DRW Securities LLC purchased a new stake in shares of BioCardia during the fourth quarter worth $72,000. Geode Capital Management LLC boosted its position in BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after acquiring an additional 27,263 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new position in BioCardia during the second quarter worth about $40,000. Institutional investors and hedge funds own 20.57% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BCDA. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of BioCardia in a research note on Tuesday, June 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.